Action Recordati - REC

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Premium

Dernier

53,35

Prix Achat

53,15

Prix Vente

54,10

Volume échangé

231 861

53,25 Fourchette du Jour 54,00

47,28 Plage de 52 semaines 54,80

Cap du marché

10,956B

Clôture Veille

54,00

Ouverture

53,80

Dernière Transaction

53.35

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

258 159

Actions en circulation

205 358 104

Rendement du Dividende

2.31%

Ratio Cours sur Bénéfices

29,30

Bénéfice par action (BPA)

1,9

Chiffre d'affairess

2,07B

Bénéfice net

389,21M

Secteur

Pharmaceutical Preparations

Industrie

Pharmaceutical Preparations

Site Web

www.recordati.it

Siège social

Milan, Lombardy, Ita

Fondé

1926

Recordati SpA est coté dans le secteur Pharmaceutical Preparations de la Italian Stock Exchange avec le ticker REC. Le dernier cours de clôture d'Recordati était de 54,00 €. Au cours de la dernière année, les actions de Recordati ont été négociées dans une fourchette de prix de 47,28 € à 54,80 €.

Recordati compte actuellement 205 358 104 actions en circulation. La capitalisation boursière d'Recordati est de 11,09 € milliard. Recordati a un ratio cours/bénéfice (ratio PE) de 29.30.

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5% Consolidated net revenue of € 1,743.1 million in the...

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE Milan, 4th October 2024 – Recordati today announces an agreement with Sanofi...

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

L’étude LINC 4 a démontré la supériorité d’Isturisa® (osilodrostat) comparé au placebo pour normaliser le cortisol au cours de la phase de 12 semaines en double aveugle, randomisée de l’étude (77...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER...

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual...

Statistically significant results from the pivotal Phase III LINC 4 study demonstrate that Isturisa® (osilodrostat) provides rapid and sustained normalisation of mean urinary free cortisol levels...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	1.6	3.09178743961	51.75	54.2	51.15	214898	52.6282681	DE
4	2.2	4.30107526882	51.15	54.2	49.16	239250	51.20783909	DE
12	-1.2	-2.19981668194	54.55	54.65	48.58	258159	51.65101826	DE
26	4.35	8.87755102041	49	54.8	47.98	248831	51.39005453	DE
52	4.47	9.14484451718	48.88	54.8	47.28	238410	50.83316528	DE
156	-0.95	-1.74953959484	54.3	55.08	34.52	235474	45.60188842	DE
260	14.55	37.5	38.8	57.9	28.26	279778	45.09472476	DE

REC - Frequently Asked Questions (FAQ)

What is the current Recordati share price?

The current share price of Recordati is 53,35 €

How many Recordati shares are in issue?

Recordati has 205 358 104 shares in issue

What is the market cap of Recordati?

The market capitalisation of Recordati is EUR 11,09B

What is the 1 year trading range for Recordati share price?

Recordati has traded in the range of 47,28 € to 54,80 € during the past year

What is the PE ratio of Recordati?

The price to earnings ratio of Recordati is 29,3

What is the cash to sales ratio of Recordati?

The cash to sales ratio of Recordati is 5,52

What is the reporting currency for Recordati?

Recordati reports financial results in EUR

What is the latest annual turnover for Recordati?

The latest annual turnover of Recordati is EUR 2,07B

What is the latest annual profit for Recordati?

The latest annual profit of Recordati is EUR 389,21M

What is the registered address of Recordati?

The registered address for Recordati is VIA MATTEO CIVITALI 1, MILAN, LOMBARDY, 20148

What is the Recordati website address?

The website address for Recordati is www.recordati.it

Which industry sector does Recordati operate in?

Recordati operates in the PHARMACEUTICAL PREPARATIONS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
WERFOLaboratorio Farmaceutico Erfo SPA	0,097 € (29,33%)	500
1WBAWalgreens Boots Alliance Inc	10,986 € (23,27%)	1,69k
SIAVSiav Spa	2,38 € (19,00%)	43k
CGFCogefeed SpA	0,72 € (16,50%)	8,5k
ATONAton Green Storage Spa	2,40 € (15,38%)	71k
WCOSMOFarmacosmo spa	0,001 € (-89,58%)	24,2k
WSBCBSicily by Car SpA	0,012 € (-38,14%)	14,66k
EPHEPH SpA	0,0501 € (-29,63%)	101,38k
WSBCCSicily by Car SpA	0,0289 € (-27,75%)	12,69k
1UAAUnder Armour Inc	7,681 € (-18,36%)	15
TITTelecom Italia SpA	0,2535 € (-2,12%)	215,34M
ISPIntesa Sanpaolo Spa	4,018 € (0,71%)	80,14M
SPMSaipem Spa	2,747 € (-0,25%)	34,38M
ENELEnel Spa	6,983 € (-0,71%)	32,34M
TITRTelecom Italia	0,296 € (-0,80%)	23,21M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Recordati SpA (REC)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Recordati SpA

REC Dernières nouvelles

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Recordati SpA (REC) Cours

Recordati SpA (REC)

Discussions et idées de trading en temps réel : négociez en toute confiance avec notre puissante plateforme.

Statistiques et détails clés

À propos de Recordati SpA

REC Dernières nouvelles

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

Recordati Rare Diseases annonce la publication dans The Journal of Clinical Endocrinology & Metabolism des résultats de l’étude de Phase III LINC 4 confirmant l'efficacité et la tolérance d’Isturisa® (osilodrostat)...

RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICON...

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual...

RECORDATI: CONTINUED DOUBLE-DIGIT GROWTH IN THE FIRST NINE MONTHS OF 2024 - REVENUE +12.0%, EBITDA(1) +11.8%, ADJUSTED NET INCOME(2) +9.5%

RECORDATI ANNOUNCES AGREEMENT TO ACQUIRE THE GLOBAL RIGHTS TO ENJAYMO®, STRENGTHENING ITS RARE DISEASES FRANCHISE

REC - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application